Genomics Services
 
 
Tyrosine Kinase Sensitivity for Abl1 Mutations
Tyrosine Kinase Inhibitors (TKIs) blocks the action of an abnormal protein that is involved in the cell divsion. The presence of an ABL1 kinase point mutation is closely linked to the development of resistance towards Tyrosine Kinase Inhibitors (imatinib, dasatinib, nilotinib or bosutinib). These mutations are found in roughly one half of cases of Tyrosine Kinase Inhibitors resistance.T315I is strongly linked to resistance, blast crisis and relapse in CML(chronic Myelogeneous Leukemia) Specifically, T315I is associated with poor outcome and confers complete resistance to imatinib and other generations of Tyrosine Kinase Inhibitor therapies. At Xcelris Labs genetic testing is done for both T315I and all other mutations of ABL1 gene.

Sample Type

Blood: 5ml of blood in EDTA vacutainers and transported at 2-8°C
 
Brochure           inquiry
 
 
EGFR (Epidermal Growth Factor Receptor)   |   ALK (Anaplastic lymphoma kinase)
BRAF (B-Raf proto-oncogene, serine/threonine kinase)   |   BRCA1 and BRCA2   |   CHECK2 (Check Point Homolog)
KRAS (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog)   |   Tyrosine Kinase Sensitivity for KIT & PDGFRA
HER2 (Human Epidermal Growth factor Receptor 2) or ERBB2   |   TP53 (Tumor Protein p53)   |   BCR-ABL
Tamoxifen   |   NRAS Mutation   |   Tyrosine Kinase Sensitivity for Abl1 Mutations
HRAS Mutation (Harvey rat sarcoma viral Oncogene Homolog)   |   DPYD Mutation (for 5FU Sensitivity)
MAPK1 Mutation Analysis
 
 
Click Here to Zoom
 
Click Here to Zoom
 
Click Here to Zoom
 
Click Here to Zoom